Furthermore, a prospective cohort study involving 341 patients with lung cancer, including 26 positive for ALK fusion gene, indicated a higher cumulative VTE incidence rate of 26.9% in ALK fusion gene-positive patients (9.2% in ALK fusion gene-negative patients) [28]. The gene discussed is ALK; the disease is lung carcinoma.